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Abstract
Objectives. To evaluate the risk–benefit profile of anti-TNF therapies in PsA and to study the predictors of
treatment response and disease remission [disease activity score (DAS)-28<2.6].
Methods. The study included PsA patients (n=596) registered with the British Society for Rheumatology
Biologics Register (BSRBR). Response was assessed using the European League against Rheumatism
(EULAR) improvement criteria. Univariate and multivariate logistic regression models were developed to
examine factors associated with EULAR response and disease remission using a range of covariates.
Poisson regression was used to calculate incidence rate ratios (IRRs) for serious adverse events (SAEs) vs
seronegative RA controls receiving DMARDs, adjusting for age, sex and baseline co-morbidity.
Results. At baseline, the mean (S.D.) DAS-28 was 6.4 (5.6). Of the patients, 70.3% were EULAR respon-
ders at 12 months. At 6 months, older patients [adjusted odds ratio (OR) 0.97 per year; 95% CI 0.95,
0.99], females (adjusted OR 0.51; 95% CI 0.34, 0.78) and patients on corticosteroids (adjusted OR
0.45; 95% CI 0.28, 0.72) were less likely to achieve a EULAR response. Over 1776.2 person-years
of follow-up (median 3.07 per person), the IRR of SAEs compared with controls was not increased (0.9;
95% CI 0.8, 1.3).
Conclusions. Anti-TNF therapies have a good response rate in PsA, and have an adverse event profile
similar to that seen in a control cohort of patients with seronegative arthritis receiving DMARD therapy.
Key words: Psoriatic arthritis, TNF inhibitors, Adalimumab, Etanercept, Infliximab, Efficacy, Risk–benefit,
Adverse events.
Introduction
The introduction of anti-TNF-a therapies (etanercept,
infliximab and adalimumab) has dramatically improved
the treatment of PsA. Randomized placebo-controlled
trials (RCTs) have shown that these therapies are effec-
tive, but observational data are still scarce [1]. A recent
meta-analysis has also reported that these agents are
superior to conventional DMARDs [2]. Further evidence
supports the improvements in symptoms, functional
status, quality of life (QoL) and radiographic progression
with anti-TNF therapies in PsA patients [3]. RCTs have
also demonstrated these therapies to be safe during
short-term use (up to 24 weeks) [1].
However, strict inclusion criteria and short duration can
limit the external validity of results obtained from RCTs
[4, 5]. The effectiveness of a treatment is determined by
how well it performs under real-life conditions, outside the
context of a randomized trial [6]. In a routine clinical prac-
tice, these agents have been shown to be more effective
than MTX [7] and result in significant improvements in QoL
and functional status in PsA patients [8].
Potential predictors associated with the continuation of
anti-TNF therapies have been explored in a number of
studies. A Swedish study of 261 PsA patients suggested
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associated with treatment continuation [9]. Whereas a
Spanish study reported that drug discontinuation was
predicted by older age [10]. A recent British study found
that the presence of other co-morbidities was associated
with patients’ withdrawal due to adverse events [11].
However, there have been minimal data published regard-
ing factors that can identify patients most likely to respond
to these therapies or show disease remission. The aim of
this study was to evaluate the efficacy–safety profile of
anti-TNF therapies in the management of PsA in routine
clinical practice, and to study the predictors of treatment
response and disease remission.
Subjects and methods
Setting
The British Society for Rheumatology Biologics Register
(BSRBR) was established in October 2001. Its aim was to
examine the long-term safety and efficacy of biologic
agents in patients with inflammatory arthropathies in the
UK [12]. The study design is a prospective, multicentre,
longitudinal, observational study. Although primarily a
study of patients with RA, the register has also collected
data on patients receiving anti-TNF therapies for other
rheumatic conditions, including PsA (2002–06 inclusive).
Subjects and controls
This analysis was restricted to patients with a physician
diagnosis of PsA registered between 2002 and 2006,
who had started etanercept (n=333), infliximab (n=171)
or adalimumab (n=92) as their first biologic drug within
6 months of registration.
During this study, etanercept (licensed in 2002) was
administered as a subcutaneous injection of 25mg twice
weekly or 50mg once weekly [13]; and adalimumab
(licensed in 2005) was administered as a subcutaneous
injection of 40mg every 2 weeks [14]. In 2004, infliximab
was licensed for use in the management of PsA at a rec-
ommended dose of 5mg/kg administered at weeks 0, 2, 6
and 8 and then every 8 weeks thereafter [15,16]. It is also
recommended that infliximab be administered in combi-
nation with MTX [15].
In order to understand the safety profile of anti-TNF
therapies in PsA, it is important to compare the rates of
observed adverse events with patients with a similar dis-
ease receiving standard DMARDs. As there was no spe-
cific PsA control population within the BSRBR, patients
with RF-negative RA, who had been recruited to the
BSRBR control cohort, were selected as a comparison
group. The BSRBR control cohort consisted of patients
with active RA [guide 28-joint count disease activity
score (DAS-28)>4.2 [17]], receiving therapy with standard
non-biologic DMARDs.
Datacollection
At the time of initiation of the anti-TNF therapy, the rheu-
matologist or rheumatology nurse specialist completed
a consultant baseline questionnaire that included details
of the patient’s age, sex, diagnosis, disease duration
and information about current disease activity, including
swollen and tender joint counts (based on the 28-joint
count), ESR and/or CRP. Details of past and present
anti-rheumatic therapies and current co-morbidities were
also recorded. Each patient completed a separate patient
baseline questionnaire that included details about current
work status, ethnicity and smoking.
Rheumatologists were sent a postal follow-up (FUP)
questionnaire every 6 months that recorded the current
DAS-28 (swollen and tender joint count, ESR/CRP and
patient global assessment). Details of all serious adverse
events (SAEs), regardless of whether or not the physician
believed they were directly related to the anti-TNF ther-
apy, were also recorded. When questionnaires were not
returned within 5 weeks, reminders were sent. At each
FUP, rheumatologists were also prompted for any missing
information from the previous questionnaire.
Any new drugs, hospitalizations, referrals and smoking
status during the past 6 months were recorded by the
patient on a 6-monthly basis for 3 years. After 2 weeks
of non-response, the reminder postcard was sent to the
patient. Following a second period of 2 weeks, the patient
was then posted another patient FUP questionnaire.
All enrolled patients were flagged for death or malignancy
with the National Health Service Information Centre (NHS
IC) [formerly known as the Office for National Statistics
(ONS)] at registration with BSRBR. The NHS IC sends
quarterly reports to the BSRBR, including a copy of the
death certificate for any patient who has died and the type
and site of any malignancies.
Analysis
Baseline co-morbidity was assessed based on the pres-
ence of one or more of a pre-specified list of co-existing
conditions: cardiovascular, pulmonary, endocrine, gastro-
intestinal (GIT), CNS and past malignancies. The preva-
lence of individual baseline co-morbidities was compared
between the PsA cases and RF-negative RA controls
adjusting for age, sex and smoking. The presence of
co-morbid conditions was compared using logistic
regression. Results were presented as adjusted odds
ratio (adjusted OR) with 95% CI [18].
Effectiveness at 6, 12 and 18 months was categorized
according to the DAS-28 using two approaches. First,
based on the European League against Rheumatism
(EULAR) response criteria [19], patients were classified
into three groups: no response, moderate response and
good response. Those patients who discontinued their
anti-TNF therapy prior to the end of each 6-month FUP,
regardless of reason, were labelled as non-responders
within that time period. Secondly, patients achieving
remission at each FUP were identified and defined
according to the EULAR criteria (DAS-28<2.6) [20].
Potential predictors of EULAR response at 6 months
were modelled using both univariate and multivariate
ordinal logistic regression, which models the probability
of achieving a higher response category, in the presence
of each predictor variable [21]. Univariate and multivariate
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tify independent predictors for disease remission [18].
Results were presented as OR with 95% CI. The following
covariates were examined in the models: baseline demo-
graphic variables [age (years), gender, smoking (yes/no),
whether the patient had additional baseline co-morbidities
(yes/no)], baseline disease-specific variables {DAS-28
as well as the individual components [high inflammatory
markers(CRP>20mg/land/orESR>28mm/h),28-tender
joint count and 28-swollen joint count], HAQ, disease dura-
tion (years)} and therapeutic variables [anti-TNF therapy
used and concurrent use of MTX, or steroids (yes/no)].
In the multivariate analyses, we used the composite
DAS-28 score as a potential predictor rather than its
individual components.
For the purpose of this analysis, a SAE was defined as
‘any adverse event that was (1) fatal, (2) life threatening, (3)
resulted in an unplanned hospitalization or prolonged an
existing hospitalization, (4) was physically disabling, (5)
resulted in a birth defect or (6) required an i.v. antibiotic’
[22]. SAEs were classified using the Medical Dictionary
for Regulatory Affairs (MedDRA) system organ classifica-
tion (SOC) [23]. Rates of SAEs were presented as events/
1000 person-years with 95% CI. Person-years were
calculated from the first day of anti-TNF therapy up to
the date of the last FUP completed up to the month
and year of drug discontinuation or death, whichever
occurred first. The date of drug discontinuation was
defined as the date of the first missed dose. Patients in
the comparison cohort contributed person-years from
their date of registration until the date of the last FUP
completed up to month and year of drug discontinuation
or death, whichever occurred first. All SAEs occurring
during this period were included in the analysis.
Incidence rate ratios (IRRs) were calculated relative to
controls using Poisson regression and were adjusted for
age, sex and baseline co-morbidity using propensity
scores [24]. All calculations were conducted using
STATA version 9.0 [24].
Ethical approval
The study was approved by the North West Multicentre
Research Ethics Committee and all subjects gave their
written consent for participation.
Results
Demographic characteristics
Baseline characteristics for all patients are shown in
Table 1. At baseline, the PsA patients were significantly
younger [mean (S.D.) age was 45.7 (11.1) years vs 59.4
(13.1) years for the control cohort; P<0.001] with a
lower proportion of females (53.0 vs 73.5%; P<0.001).
The mean (S.D.) disease duration was 12.4 (8.7) and 8.5
(9.7) years and the corresponding mean (S.D.) DAS-28 was
6.4 (5.6) and 5.0 (1.4), respectively, in the anti-TNF
and control cohorts. There were no significant statisti-
cal differences between the three anti-TNF cohorts
in age (P=0.325), sex (P=0.581) or disease duration
(P=0.384). There was also no significant statistical differ-
ence among patients receiving the three anti-TNF thera-
pies in DAS at baseline, as shown in Table 1. It was noted
that 78% of the patients receiving infliximab received the
dose recommended for RA (3mg/kg), the rest receiving
the full 5mg/kg.
Baseline co-morbidity
The overall prevalence of co-morbidities in the PsA cases
and RF-negative RA controls was similar. In the control
cohort, 28.6% of the patients had no co-morbid condition,
33.8% had one and 37.6% had more than one. In com-
parison, 37.0% of the anti-TNF cohort had no co-morbid
condition, 30.7% had one and 32.3% had more than one.
The most frequent co-morbid condition was hypertension
in the anti-TNF (29.2%) and control (33.8%) cohorts, as
shown in Table 2. There were no significant differences
in the prevalence of any co-morbid diseases between
the two cohorts (Table 2) after adjusting for age, sex
and smoking status, with the exception of asthma,
TABLE 1 Demographic and disease characteristics of PsA cases and seronegative RA control cohorts at baseline
Characteristics
Control
(n=1115)
All PsA cohort
(n=596)
Etanercept
(n=333)
Infliximab
(n=171)
Adalimumab
(n=92) P-value
Demographic characteristics
Age 59.4 (13.1) 45.7 (11.1) 45.8 (11.1) 44.8 (11.0) 47.0 (11.6) 0.325
Female, n (%) 820 (73.5) 316 (53.0) 170 (51.1) 94 (55.0) 49 (53.3) 0.581
Disease duration, years 8.5 (9.7) 12.4 (8.7) 12.8 (9.0) 12.2 (8.0) 11.4 (8.4) 0.384
Disease characteristics
Tender joint count 8.7 (7.1) 13.4 (7.7) 13.5 (7.6) 14.1 (8.1) 12.1 (7.1) 0.346
Swollen joint count 6.0 (5.4) 8.9 (6.1) 8.8 (6.1) 8.8 (6.4) 9.7 (5.7) 0.293
ESR 32.1 (23.9) 40.5 (29.0) 39.4 (28.1) 44.2 (31.4) 37.7 (27.4) 0.459
CRP 27.8 (32.4) 39.3 (47.1) 35.4 (41.8) 47.8 (50.0) 35.0 (56.6) 0.787
DAS-28 5.0 (1.4) 6.4 (5.6) 6.1 (1.2) 7.3 (10.1) 6.0 (1.0) 0.464
HAQ, median (interquartile range) 1.9 (1.4–2.3) 1.9 (1.4–2.3) 1.8 (1.4–2.3) 2.0 (1.4–2.4) 1.8 (1.1–2.3) 0.581
Values are mean (S.D.) unless otherwise specified; P-value tests for significant differences between the three anti-TNF
therapies’ cohorts.
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(adjusted OR=0.80; 95% CI 0.65, 0.98).
Treatment response anddisease remission
On the basis of EULAR criteria, 37.5% of the anti-TNF
cohort reached a good response and 38.3% reached a
moderate response at 6 months. The EULAR response
appeared to be maintained at 12 and 18 months (Table 3).
At12and18months,respectively,70.3%and68.2%ofthe
patients were responders on the basis of EULAR criteria.
There were no significant differences in EULAR
response rates at 6 (P=0.679), 12 (P=0.904) and 18
(P=0.583) months between the three anti-TNF therapies.
EULAR response rates for the whole anti-TNF cohort were
also similar in patients receiving anti-TNF agents in com-
bination with MTX (78.1% at 6 months), another DMARD
(73.3%) or anti-TNF monotherapy (79.5%).
Disease remission was achieved by 133 (27.5%), 160
(36.1%) and 131 (35.2%) patients in the anti-TNF cohort at
6, 12 and 18 months, respectively. In the etanercept
cohort, 80 (30.9%), 91 (37.3%) and 77 (36.5%) patients;
in the infliximab cohort, 28 (19.7%), 37 (28.9%) and
32 (29.6%); and in the adalimumab cohort, 25 (30.1%),
32 (45.1%) and 22 (41.5%) achieved remission at 6,
12 and 18 months, respectively.
Predictors of treatment responseand disease
remission at 6 months
Table 4 shows the results from the univariate and multi-
variate analyses, examining predictors of (i) achieving
a higher EULAR response category and (ii) disease remis-
sion. For the EULAR response, both univariate and multi-
variate analyses suggested that each additional year of
age (adjusted OR 0.98, 95% CI 0.96, 0.99 and adjusted
OR 0.97, 95% CI 0.95, 0.99, respectively), being female
(adjusted OR 0.49, 95% CI 0.35, 0.70 and adjusted OR
0.51, 95% CI 0.34, 0.78, respectively) and receiving corti-
costeroids (adjusted OR 0.48, 95% CI 0.31, 0.74 and
adjusted OR 0.45, 95% CI 0.28, 0.72, respectively)
resulted in lower response rates.
For disease remission at 6 months, older patients and
females were less likely to achieve disease remission
in both the univariate (OR 0.97, 95% CI 0.95, 0.99 and
OR 0.37, 95% CI 0.25, 0.55, respectively) and multi-
variate models (adjusted OR 0.96, 95% CI 0.94, 0.99
and adjusted OR 0.34, 95% CI 0.21, 0.57, respectively).
Patients with inflammation were also less likely to achieve
disease remission (OR 0.54, 95% CI 0.31, 0.97) in the
univariate model. In addition, there was a non-statistically
significant trend towards lower remission in patients
receiving concomitant steroid therapy and in those with
higher HAQ scores in both models (Table 4). The univari-
ate model also showed that patients with elevated base-
line laboratory values for inflammation (CRP>20mg/l or
ESR>28mm/h) had lower response rates and disease
remission.
SAEs
For the anti-TNF cohort (n=596) over 1776.2 person-
years of FUP (median 3.07 per person), there were 211
TABLE 2 Baseline co-morbidity in PsA cases and seronegative RA control cohorts at baseline
Co-morbid
disorders
Control
(n=1115), n (%)
All PsA cohort (n=596)
n (%) Adjusted OR
a (95% CI)
Cardiovascular disorders
Hypertension 377 (34) 174 (29) 0.96 (0.87, 1.07)
Angina 93 (8) 9 (2) 0.72 (0.47, 1.11)
Myocardial infarction 50 (4) 6 (1) 0.64 (0.34, 1.20)
Stroke 38 (3) 13 (2) 0.79 (0.56, 1.11)
Pulmonary disorders
Bronchitis and emphysema 13 (1) 6 (1) 1.07 (0.59, 1.93)
Asthma* 167 (15) 51 (9) 0.80 (0.65, 0.98)
COPD 98 (9) 26 (4) 0.96 (0.75, 1.22)
Endocrine disorders
Diabetes 81 (7) 32 (5) 0.97 (0.74, 1.26)
Hyperthyroidism 44 (4) 8 (1) 0.82 (0.53, 1.26)
GIT disorders
Peptic ulcer disease 75 (7) 41 (6.88) 1.19 (0.97, 1.46)
Liver disease 23 (2) 28 (4.70) 1.20 (0.91, 1.56)
Renal disease 31 (3) 12 (2.01) 0.91 (0.59, 1.40)
CNS disorders
Demyelination 7 (1) 0 (0) –
Epilepsy 18 (2) 15 (3) 1.02 (0.70, 1.49)
Depression 195 (17) 114 (19) 1.08 (0.94, 1.23)
Past malignancy 71 (6) 13 (2) 0.70 (0.45, 1.06)
aORs are calculated versus control and adjusted for age, sex and smoking. *P<0.05. COPD: chronic obstructive pulmonary
disease.
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16 cardiac disorders, 14 GIT disorders, 12 musculoskele-
tal and CTDs, 14 neoplasms and 13 nervous system dis-
orders, as shown in Table 5. Whereas for the control
cohort (n=1115) and >3409.9 person-years of FUP,
there were 624 SAEs. Furthermore, there were no reports
of tuberculosis (TB) in any of the two cohorts. When
adjusted for age, sex and baseline co-morbidity, there
were no significant differences between the anti-TNF
and control cohorts in the IRRs for SAEs (Table 5).
There were 10 cases of serious drug hypersensitivity
and one of a serious opportunistic infection (cold sore
and right facial swelling due to herpes simplex) in the
infliximab cohort vs seven cases of serious drug hyper-
sensitivity and three of serious opportunistic infection
[lower respiratory tract infections—Aspergillus (1),
Pneumocystis jiroveci (2)] in the control cohort. There
were also 15, 8, 2 and 49 deaths in the etanercept, inflix-
imab, adalimumab and control cohorts, respectively.
In total, there were 81 malignancies reported in various
sites (14 anti-TNF and 67 DMARD control). Of note there
were five cases of lymphoma in the control group and
no cases in the anti-TNF group. There were 29 reports
of skin cancer in total including 17 basal cell cancers
(4 in controls, 13 in anti-TNF), 8 non-melanoma skin can-
cers not otherwise specified (2 anti-TNF, 6 controls) and
4 melanomas (2 in each group). The overall risk of cancer
was not increased in the anti-TNF cohort compared with
the control group (IRR 1.0; 95% CI, 0.5, 2.2).
Discussion
The study found that 75.8, 70.3 and 68.2% of the studied
PsA cohort were EULAR responders at 6, 12 and 18
months, respectively. Similar findings have been observed
in the South Swedish Arthritis Treatment Group register in
which 75% of their PsA cohort (n=261) were EULAR
responders at 12 months [9], whereas a previous study
TABLE 3 Improvements in disease activity over the FUP period in the PsA cohort
All PsA
cohort (n=596)
Etanercept
(n=333)
Infliximab
(n=171)
Adalimumab
(n=92)
6-Month follow-up (n
a=480)
Baseline DAS-28,
b mean (S.D.) 6.2 (1.1) 6.1 (1.2) 6.3 (1.1) 6.0 (1.0)
6-Month DAS-28, mean (S.D.) 3.5 (1.5) 3.3 (1.4) 3.9 (1.6) 3.32 (1.37)
Mean diff. (S.D.) in DAS-28 2.6 (1.6) 2.8 (1.6) 2.3 (1.7) 2.66 (1.40)
EULAR response
Good, n (%) 180 (38) 109 (43) 35 (24) 36 (43)
Moderate, n (%) 184 (38) 92 (37) 55 (38) 37 (45)
None, n (%) 116 (24) 51 (20) 55 (38) 10 (12)
EULAR response in those remaining on initial therapy
Good, n (%) 180 (45) 109 (40) 35 (338) 36 (47)
Moderate, n (%) 184 (46) 92 (42) 55 (52) 37 (48)
None, n (%) 35 (9) 16 (83) 15 (14) 4 (5)
12-Month follow-up (n
a=441)
12-Month DAS-28, mean (S.D.) 3.4 (1.5) 3.2 (1.4) 3.7 (1.7) 3.2 (1.5)
Mean diff. (S.D.) in DAS-28 2.7 (1.7) 2.9 (1.6) 2.4 (1.9) 2.9 (1.6)
EULAR response
Good, n (%) 183 (42) 112 (48) 35 (26) 36 (50)
Moderate, n (%) 127 (29) 71 (30) 36 (27) 20 (28)
None, n (%) 131 (29) 51 (22) 64 (47) 16 (22)
EULAR response in those remaining on initial therapy
Good, n (%) 183 (53) 112 (55) 35 (43) 36 (60)
Moderate, n (%) 127 (37) 71 (35) 36 (44) 20 (33)
None, n (%) 34 (10) 19 (10) 11 (13) 4 (7)
18-Month follow-up (n
a=384)
18-Month DAS-28, mean (S.D.) 3.3 (1.5) 3.3 (1.4) 3.5 (1.6) 3.2 (1.5)
Mean diff. (S.D.) in DAS-28 2.8 (1.7) 2.9 (1.7) 2.7 (1.8) 2.8 (1.7)
EULAR response
Good, n (%) 150 (39) 89 (43) 35 (29) 26 (48)
Moderate, n (%) 112 (29) 71 (34) 28 (23) 13 (24)
None, n (%) 122 (32) 48 (23) 59 (48) 15 (28)
EULAR response in those remaining on initial therapy
Good, n (%) 150 (53) 89 (52) 35 (53) 26 (58)
Moderate, n (%) 112 (40) 71 (42) 28 (42) 13 (29)
None, n (%) 21 (7) 12 (7) 3 (5) 6 (13)
aNumber of patients with complete data on DAS-28 at follow-up.
bBaseline DAS-28 score in only those who had data on
disease activity at the corresponding follow-up questionnaire.
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Variable
Higher EULAR response, OR (95% CI) Disease remission, OR (95% CI)
Univariate
analysis
Multivariate
analysis
Univariate
analysis
Multivariate
analysis
Demographic variables
Age at start of therapy 0.98* (0.96, 0.99) 0.97* (0.95, 0.99) 0.97* (0.95, 0.99) 0.96* (0.94, 0.99)
Female 0.49* (0.35, 0.70) 0.51* (0.34, 0.78) 0.37* (0.25, 0.55) 0.34* (0.21, 0.57)
Smoking (yes/no) 0.96 (0.68, 1.36) 1.07 (0.71, 1.59) 0.76 (0.51, 1.14) 0.74 (0.45, 1.20)
Baseline co-morbidity
a (yes/no) 0.88 (0.60, 1.29) 0.83 (0.53, 1.30) 0.77 (0.51, 1.16) 0.64 (0.38, 1.06)
Disease variables
Baseline DAS-28 1.01 (0.99, 1.02) 0.99 (0.98, 1.02) 0.99 (0.98, 1.01) 0.99 (0.96, 1.02)
Baseline HAQ 0.78* (0.62, 0.98) 0.85 (0.66, 1.08) 0.78 (0.59, 1.03) 0.85 (0.63, 1.15)
Disease duration (years) 1.01 (0.99, 1.03) 1.02 (0.99, 1.04) 0.99 (0.97, 1.02) 1.00 (0.97, 1.04)
Inflammation
b 0.54* (0.30, 0.96) – 0.54* (0.31, 0.97) –
TJC 1.00 (0.98, 1.03) – 0.97 (0.95, 1.00) –
SJC 1.01 (0.99, 1.05) – 0.99 (0.95, 1.02) –
Therapeutic variables: concurrent use of
DMARDs 1.31 (0.42, 4.06) 0.82 (0.19, 3.55) 0.42 (0.09, 1.93) 0.44 (0.05, 4.18)
Steroids 0.48* (0.31, 0.74) 0.45* (0.28, 0.72) 0.57 (0.32, 1.01) 0.55 (0.29, 1.02)
Biological therapy: etanercept is the reference category
Infliximab 0.55 (0.37, 1.82) 0.60 (0.38, 1.95) 0.57 (0.35, 1.94) 0.69 (0.39, 1.22)
Adalimumab 1.01 (0.63, 1.63) 0.81 (0.44, 1.49) 1.16 (0.67, 1.99) 0.97 (0.46, 2.04)
*P<0.05.
aIncludes any of hypertension, angina, ischemic heart disease, stroke, pulmonary fibrosis, asthma, chronic obstruc-
tive pulmonary disease, diabetes, thyroid disease, peptic ulcers, hepatic disease, renal disease, demyelinating disease,
epilepsy, depression, TB and cancer.
bInflammation (CRP>20 mg/l or ESR>28 mm/h). SJC: swollen joint count; TJC:
tender joint count.
TABLE 5 SAEs in PsA cases and seronegative RA control cohorts
SAEs (MedDRA SOC)
Control
(n=1115)
All anti-TNF
(n=596)
Total no. of SAEs 624 211
Total person-years of FUP 3409.9 1776.2
Total IRRs
a (95% CI) Reference 0.9 (0.8, 1.3)
Infections, n 137 53
Rate/1000 person-years (95% CI) 19.6 (18.7, 20.6) 11.2 (10.3, 12.1)
IRRs
a (95% CI) Reference 0.7 (0.5, 1.1)
Neoplasms benign, malignant and unspecified, n 67 14
Rate/1000 person-years (95% CI) 19.1 (18.0, 20.3) 18.1 (15.9, 20.5)
IRRs
a (95% CI) Reference 1.0 (0.5, 2.2)
Cardiac disorders, n 56 16
Rate/1000 person-years (95% CI) 4.3 (3.7, 5.0) 2.6 (1.9, 3.4)
IRRs
a (95% CI) Reference 0.6 (0.3, 1.1)
GIT disorders, n 31 14
Rate/1000 person-years (95% CI) 10.5 (9.2, 11.9) 10.5 (8.7, 12.7)
IRRs
a (95% CI) Reference 0.9 (0.5, 1.4)
Musculoskeletal and CTDs, n 48 12
Rate/1000 person-years (95% CI) 21.6 (20.1, 23.1) 17.7 (15.3, 20.4)
IRRs
a (95% CI) Reference 0.6 (0.2, 1.5)
Nervous system disorders, n 43 13
Rate/1000 person-years (95% CI) 29.2 (27.2, 31.3) 27.8 (24.3, 31.6)
IRRs
a (95% CI) Reference 1.0 (0.5, 2.1)
aIRRs were calculated vs controls and were adjusted for age, sex and baseline co-morbidity using propensity score.
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patients on etanercept and infliximab reported that
68% of these patients were classified as responders at
6 months [25]. The EULAR response rate was similar
among the three anti-TNF therapies up to 18 months
despite the lower dose used in the infliximab cohort.
The use of the lower dose of infliximab (3mg/kg) may
reflect the fact that infliximab did not receive its UK
licence for use in PsA until 2004 and national guidelines
on use were not issued until 2005, near the end of the
recruitment phase for this study. Thus, most physicians
may have applied the same dosing regimen as used for
RA on these patients. Small numbers precluded an ana-
lysis of differential response among those patients receiv-
ing the two prescribed doses. The EULAR response rate
was also similar in patients receiving anti-TNF agents in
combination with MTX, another DMARD or anti-TNF
monotherapy at 6 months. Disease remission was
achieved by 27.5, 36.1 and 35.2% patients in the whole
anti-TNF cohort at 6, 12 and 18 months, respectively.
Response to therapy was measured using the DAS-28
and the EULAR response criteria. A full set of domains to
assess improvements in PsA patients would ideally
include outcomes that measure skin involvement, dactyl-
itis, enthesitis, spine involvement and radiological out-
come. For feasibility reasons, we used the DAS-28,
which was originally developed specifically for RA, but
has been shown to perform better than PsARC in RCTs
of PsA [26], and to be discriminant and responsive in
observational cohorts of PsA [9].
At 6 months, female and older patients achieved lower
improvements in their EULAR response and disease
remission. Patients with higher baseline HAQ also experi-
enced lower EULAR response and disease remission but
this did not reach statistical significance. These results are
closely related to the predictors reported for RA patients
within the same register where higher baseline HAQ was
associated with lower response and females were less
likely to achieve remission [25]. It was also reported that
concurrent use of MTX and current smokers were asso-
ciated with higher and lower response rates in RA
patients, respectively. These covariates did not reach sta-
tistical significance in our PsA cohort, but patients receiv-
ing corticosteroids experienced statistically significant
lower EULAR response rates. Our results are also similar
to those of the South Swedish Arthritis Treatment Group
Register where they reported that lower baseline HAQ
was associated with better treatment outcomes in a
cohort of 1565 RA patients [27]. To our knowledge, no
study has explored potential predictors for treatment
efficacy in PsA patients.
During the FUP, there were no significant differences
between the PsA cohort receiving anti-TNF therapies
and RF-negative RA control cohort receiving DMARDs in
the IRRs for all SAEs. Likewise, the incidence of malig-
nancy was similar in both the anti-TNF and control
cohorts, but these numbers are low and likely to be under-
powered to detect any important difference in malignancy
if one existed. There is also a selection bias that affects
the influence of anti-TNF agents on malignant outcome,
as BSR guidelines suggest that all anti-TNF-treated
patients had to be free of malignancy for the 10 years
prior to commencing treatment. We found a lower but
insignificant prevalence of past-malignancy at baseline
in the anti-TNF cohort than in the control cohort. The
majority of the reported malignancies also occurred
within the first year following registration [mean time
(S.D.) from registration to the reported tumour date was
265.4 (230.3 days)]. This period of time is likely to be too
short for the anti-TNF agents to play a pathogenic role in
tumour genesis, raising the potential risk of protopathic
bias.
To our knowledge, this is the largest longitudinal obser-
vational study of a large unselected population of patients
with PsA receiving anti-TNF therapy in routine clinical
practice. The present results can be considered as a
reflection of the treatment outcomes as they have
occurred in the real world of routine clinical practice, as
treatments were open-labelled, treatment decisions were
not randomized but rather left to rheumatologists, and
there were no restrictions to patient participation.
Limitations to this study emerged from the rationale
behind the construction of this register. Its aim was initially
to establish the long-term safety and efficacy of biologic
agents in patients with RA in the UK [12]. As data collec-
tion started, a subgroup of PsA patients receiving
anti-TNF therapies was constructed over time (n=596).
Ideally, a parallel cohort of controls with PsA receiving
DMARDs would have been collected with which to com-
pare the rates of SAEs. As this was not available, the most
closely related cohort (RF-negative RA patients receiving
DMARDs) within the BSRBR control cohort was selected.
A second limitation is that the collected data did not
include any assessment of the impact on psoriatic skin
lesions. Finally, as there is no definition for disease
remission in the literature for PsA, we used one that is
routinely applied in RA.
In conclusion, anti-TNF therapies were effective in the
management of PsA with no added risk to the incidence of
SAEs compared with conventional DMARDs; although the
anti-TNF-treated patients had probably somewhat better
malignancy and respiratory history at baseline. The mean
FUP time on the BSRBR is still too short to comment on
the safety profile of these agents beyond 3 years. There is
still a need to continue FUP of these therapies in PsA for
longer periods.
Rheumatology key messages
. Anti-TNF therapies are effective in PsA.
. Increasing age, female sex and concurrent use
of corticosteroids predicted poorer treatment
response.
. Over 1776.2 person-years, anti-TNF therapies had
a comparable safety profile to DMARDs.
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